Related Experiment Video
Updated: Apr 26, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
New advances in the treatment of atrial fibrillation: focus on stroke prevention
1University of Birmingham Centre for Cardiovascular Sciences, City Hospital , Birmingham , UK.
Insights
Vitamin K antagonists (VKA) remain important for stroke prevention in atrial fibrillation (AF), but non-vitamin K antagonist oral anticoagulants (NOACs) offer convenience. NOACs are becoming more attractive options for managing AF-related risks.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Management
Background:
- Atrial fibrillation (AF) is a prevalent arrhythmia linked to substantial mortality and morbidity.
- Stroke prevention in AF is critical, with advancements including non-vitamin K antagonist oral anticoagulants (NOACs).
Purpose of the Study:
- To review the efficacy and safety of antiplatelet agents, VKAs, and NOACs for stroke prevention in AF.
- To focus on NOACs, their limitations, and special considerations.
- To assess non-pharmacological antithrombotic procedures.
Main Methods:
- Extensive PubMed literature search.
- Review of antiplatelet agents, vitamin K antagonists (VKAs), and non-vitamin K antagonist oral anticoagulants (NOACs).
Main Results:
- VKAs remain vital due to versatility, while NOACs offer convenience and fewer interactions.
- The role of antiplatelet agents in AF stroke prevention is expected to decrease.
- Left atrial appendage occlusion devices show promise for managing AF thromboembolism risks.
Conclusions:
- NOACs present attractive alternatives to VKAs for stroke prevention in AF.
- The selection of NOACs depends on individual patient factors.
- Non-pharmacological interventions like left atrial appendage occlusion may significantly impact future AF management.
Introduction:
Atrial fibrillation (AF) is the most common arrhythmia and brings about significant mortality and morbidity as a result of heart failure and ischemic stroke. Besides vitamin K antagonists (VKA), several new pharmacological agents (nonvitamin K antagonist oral anticoagulants [NOACs]) and procedures have since been developed to improve stroke prevention efforts in AF.
Areas Covered:
This paper will discuss the antiplatelet agents, VKA and NOACs, and their efficacy and safety for stroke prevention in AF. Focus will be placed on the NOACs, their limitations and special considerations. A short assessment of other nonpharmacological antithrombotic procedures will also be made. An extensive PubMed search was used to identify suitable papers.
Expert Opinion:
Despite the advent of NOACs, the VKAs will remain as an important oral anticoagulant due to its versatility. However, convenience and limited food or drug interactions will make NOACs attractive options. The choice between various NOACs will depend on several important factors as illustrated below. Over time, the role for antiplatelet agents will gradually diminish. Left atrial appendage occlusion devices have shown promising results and may have the potential to change the way clinicians manage thromboembolism risks related to AF.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:25Dysrhythmias VI: Management of Dysrhythmias
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Atherosclerosis III: Management
01:23Atherosclerosis IV: Nursing Management
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...